More about Global Health Limited
Fundamentals for Global Health Limited
Regulatory Filings for Global Health Limited
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
Fundamentals for Global Health Limited
Business Operations:
Sector: HealthcareIndustry: Medical Care Facilities
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in New Delhi, India.
Revenue projections:
Global Health Limited is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.
Financial Ratios:
| currentRatio | 2.671000 |
|---|---|
| forwardPE | 37.423733 |
| debtToEquity | 29.869000 |
| earningsGrowth | 0.420000 |
| revenueGrowth | 0.245000 |
| grossMargins | 0.525450 |
| operatingMargins | 0.152920 |
| trailingEps | 20.640000 |
| forwardEps | 32.273640 |
MEDANTA's current ratio 2.671, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, MEDANTA can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
Global Health Limited's low Debt-to-Equity ratio shows the company avoids heavy reliance on debt. This balanced approach reduces financial risk, as it maintains a healthy equity position without excessive leverage, providing greater financial stability and flexibility.
Global Health Limited's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.
MEDANTA's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for MEDANTA's financial performance.
Price projections:
Price projections for Global Health Limited have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in Global Health Limited's future potential and financial outlook among analysts.
Recommendation changes over time:
Analysts have shown a buy bias for Global Health Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Global Health Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
How Independent Directors Failed Rs 2,500 Crore in Value
India’s Stock Market May Be Sitting on a Trap